Trials / Completed
CompletedNCT00062491
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- BioNumerik Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Karenitecin (BNP1350) | Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops. |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2003-06-01
- Completion
- 2005-11-01
- First posted
- 2003-06-12
- Last updated
- 2020-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00062491. Inclusion in this directory is not an endorsement.